Fundraising Fox

Adaptilens

Chestnut Hill, US · Founded 2019 · 2 known investors

Find your way into Adaptilens

190 people in our graph share verified history with the Adaptilens team — schools, employers, funds. One of them is your warm intro.

Logan Hilleunlockedknows Liane Clamen · together at Harvard Medical School (overlapped)
×8knows the team · via Harvard Medical School
knows the team · via Beth Israel Deaconess Medical Center
×2knows the team · via Massachusetts Eye and Ear

Adaptilens develops a biomimetic accommodating intraocular lens (A-IOL) for cataract and vision correction, an ophthalmic medical device. The company's work centers on IOL research, development, and clinical studies.

BiotechHardwareHealthtechMedical Devices

Founders & leadership

Adaptilens was founded in 2019 by Liane Clamen.

LCLiane Clamen
Liane ClameninFounder and CEOLiane Clamen completed her MD and BA at Harvard University and trained in ophthalmology at Massachusetts Eye and Ear. She has invented multiple ophthalmic medical devices, including a punctal plug drug delivery system and an anterior capsulotomy device, and is the founder of Adaptilens, which develops an accommodating intraocular lens.

Board

JGJamie Goldstein
Jamie Goldsteinin𝕏Board directorFounding/Managing Partner at Pillar VC
JA
John AndresBoard director
TK
Terry KimBoard director
WS
William SheaBoard director
RD
Robert DorisBoard director

Investors · 2

Pillar VC✓ verifiedBoston · $50K – $4M

Also in the syndicate · 1

Accanto Partners

Funding

SEC filings, press & company announcements

$27.7M disclosed across 4 of 6 rounds · 2020–2026

▶$7MraisedMay 2024 · 12 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jamie GoldsteinDirector
  • C. Gianna LucaDirector
  • William SheaDirector
  • Liane ClamenExecutive Officer, Director
Offering amount
$16M
Amount sold
$7M
Proceeds to insiders
$300K
First sale
Apr 2024
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.6MraisedJun 2023 · 12 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • John AndresDirector
  • Terry KimDirector
  • William SheaDirector
  • Robert DorisDirector
  • Liane ClamenExecutive Officer, Director
  • Jamie GoldsteinDirector
Offering amount
$1.6M
Amount sold
$1.6M
First sale
Mar 2023
Incorporated
Limited Liability Company, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Adaptilens closes Series A financing round of $17.5 million to help drive development of the company's Accommodating Intraocular Lens | Ophthalmology Times - Clinical Insights for Eye Specialistsophthalmologytimes.com · May 2026Adaptilens: $17.5 MIllion Raised For Transforming The Care For Cataract Surgerypulse2.com · May 2024Harvard M.D.-founded startup Adaptilens raises $17.5M Series A - Boston Business Journalbizjournals.com · Apr 2024Adaptilens Raises $17.5M in Series A Fundingfinsmes.com · Apr 2024Adaptilens fetches $1.6m seedventurecapitaljournal.com · Nov 2020Adaptilens Announces $1.6 Million in Seed Funding to Revolutionize the Way Vision is Correctedprweb.com · Nov 2020

Frequently asked questions

What does Adaptilens do?
Adaptilens develops a biomimetic accommodating intraocular lens (A-IOL) for cataract and vision correction, an ophthalmic medical device. The company's work centers on IOL research, development, and clinical studies.
Who founded Adaptilens?
Adaptilens was founded by Liane Clamen in 2019.
Who are Adaptilens's investors?
Adaptilens's investors include Pillar VC.
How much funding has Adaptilens raised?
Adaptilens has disclosed $27.7M raised across 4 of its 6 known rounds.
Where is Adaptilens headquartered?
Adaptilens is headquartered in Chestnut Hill, US.